PBYI PUMA BIOTECHNOLOGY, INC.
Data as of close
Healthcare · Pharmaceutical Preparations
PUMA BIOTECHNOLOGY, INC. (PBYI) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $529 million. Shares last traded at $10.24, 10.2% below their 52-week high. Over the past year the stock is up 99.6%. PBYI trades at a price-to-earnings ratio of 19.78, above the Pharmaceutical Preparations median of 15.73. Net profit margin is 11.6%, above the peer median of -7.4%. Revenue declined 0.9% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.16 | 2026-08-06 |
| Q1 2026 | -$0.07 | 2026-05-07 |
| Q4 2025 (derived) | $0.26 | 2026-02-26 |
| FY 2025 | $0.61 | 2026-02-26 |
| Q3 2025 | $0.17 | 2025-11-06 |
| Q2 2025 | $0.12 | 2025-08-07 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Pharmaceutical Preparations peers
PBYI vs 14 industry peers (Pharmaceutical Preparations), by market cap. Data as of close
| LLY | Lilly (Eli) | $1.33T | 48.07 | 15.33 | 31.9% | -0.12% |
| JNJ | Johnson & Johnson | $640.8B | 39.81 | 6.45 | 16.2% | -1.76% |
| ONC | Beone Medicines Ltd. | $524.6B | 800.05 | 85.59 | 10.7% | -1.72% |
| ABBV | AbbVie | $503.8B | 48.71 | 7.63 | 15.7% | -1.30% |
| MRK | Merck | $356.9B | 112.49 | 5.36 | 4.8% | -2.57% |
| ABT | Abbott Laboratories | $190.6B | 30.37 | 4.22 | 13.9% | -0.78% |
| PFE | Pfizer | $171.2B | 42.46 | 2.69 | 6.3% | -2.18% |
| VRTX | Vertex Pharmaceuticals | $134.7B | 33.87 | 10.40 | 30.7% | -6.81% |
| BMY | Bristol Myers Squibb | $126.1B | 13.65 | 2.52 | 18.5% | -2.09% |
| REGN | Regeneron Pharmaceuticals | $100.7B | 20.91 | 5.96 | 28.5% | +1.30% |
| TEVA | Teva Pharmaceutical Industries Ltd | $48.9B | 96.62 | 2.84 | 2.9% | +3.00% |
| ZTS | Zoetis | $34.3B | 13.11 | 3.60 | 27.5% | -0.18% |
| RPRX | Royalty Pharma Plc | $29.5B | 36.25 | 11.65 | 32.1% | -0.26% |
| ROIV | Roivant Sciences Ltd. | $26.0B | — | 3458.17 | — | +0.47% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.